The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Alvotech (NASDAQ:ALVO – Get Free Report) is expected to issue its quarterly earnings data after the market closes on ...

Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...